Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

George TJ, Lin T, Nassour I, Rogers SC, Jang T, Sahin I, Ramnaraign BH, Fabregas J, Hitchcock K, Liu G, Russell KB, Turk AA, Kayaleh O, Fan ZH, DeRemer DL, Thomas RM, Lee JH, Hughes SJ

Open source

DOI: 10.1093/oncolo/oyag250
Published: 2026 Aug 6
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag250,
  title = {Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.},
  author = {George TJ and Lin T and Nassour I and Rogers SC and Jang T and Sahin I and Ramnaraign BH and Fabregas J and Hitchcock K and Liu G and Russell KB and Turk AA and Kayaleh O and Fan ZH and DeRemer DL and Thomas RM and Lee JH and Hughes SJ},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyag250},
  url = {https://doi.org/10.1093/oncolo/oyag250}
}

RIS

TY  - JOUR
TI  - Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.
AU  - George TJ
AU  - Lin T
AU  - Nassour I
AU  - Rogers SC
AU  - Jang T
AU  - Sahin I
AU  - Ramnaraign BH
AU  - Fabregas J
AU  - Hitchcock K
AU  - Liu G
AU  - Russell KB
AU  - Turk AA
AU  - Kayaleh O
AU  - Fan ZH
AU  - DeRemer DL
AU  - Thomas RM
AU  - Lee JH
AU  - Hughes SJ
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyag250
UR  - https://doi.org/10.1093/oncolo/oyag250
ER  -

APA

TJ, G., T, L., I, N., SC, R., T, J., I, S., BH, R., J, F., K, H., G, L., KB, R., AA, T., O, K., ZH, F., DL, D., RM, T., JH, L., & SJ, H. (2026). Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.. The oncologist. https://doi.org/10.1093/oncolo/oyag250

Source records

pubmed · retrieved 2026-09-26T12:48:42.839Z